Par Drugs & Chemicals Ltd

Par Drugs & Chemicals Management Change

Par Drugs re-appointed its statutory auditor and executive director/CEO. These appointments were approved at the company's 27th Annual General Meeting.

Par Drugs & Chemicals Annual General Meeting

Par Drugs and Chemicals Limited held its 27th Annual General Meeting on September 26, 2026. Management reviewed the company's financial performance and business affairs during the session.

Par Drugs & Chemicals Other Announcement

Par Drugs and Chemicals Limited is notifying shareholders about access to the FY 2025-26 Annual Report and 27th AGM notice via web-link.

Par Drugs & Chemicals Management Change

Par Drugs and Chemicals Limited has re-appointed M/s. Siddhpura & Co. as Internal Auditor and M/s. Maulin Shah & Associates as Cost Auditor.

Par Drugs & Chemicals Annual General Meeting

Par Drugs and Chemicals Limited has scheduled its 27th Annual General Meeting for September 26, 2026, in Vadodara to transact scheduled ordinary and special business.

Par Drugs & Chemicals Q4 FY26 Results: Net Profit ₹13.1 Cr, Down 2.2% YoY

Par Drugs & Chemicals Ltd reported revenue from operations of ₹103.7 Cr (+2.7% YoY) and net profit of ₹13.1 Cr (-2.2% YoY) for Q4 FY26.

Key figure

Net profit ₹13.1 Cr · -2.2% YoY

Par Drugs & Chemicals Board Meeting Date

Par Drugs and Chemicals Limited has scheduled a board meeting for August 22, 2026. The meeting will address other business matters.

Par Drugs & Chemicals Q1 FY27 Results: Net Profit ₹4.7 Cr, Up 42.4% YoY

Par Drugs & Chemicals Ltd reported revenue from operations of ₹31.3 Cr (+20.4% YoY) and net profit of ₹4.7 Cr (+42.4% YoY) for Q1 FY27.

Key figure

Net profit ₹4.7 Cr · +42.4% YoY

Par Drugs & Chemicals Legal & Regulatory

Par Drugs & Chemicals Ltd submitted a SEBI Regulation 74(5) compliance certificate for the quarter ended June 30, 2026. The filing confirms dematerialisation of securities with MUFG Intime India.

Par Drugs & Chemicals Legal & Regulatory

Par Drugs and Chemicals secured a rectification order deleting a tax demand of ₹0.20 Crore. The demand is now nil, with no material financial impact.

Value

₹0.20 Cr

Par Drugs & Chemicals Legal & Regulatory

Par Drugs and Chemicals received a rectification order deleting a prior income tax demand. The demand is now nil, with no financial impact.

Par Drugs & Chemicals Legal & Regulatory

Par Drugs received a ₹0.20 Crore income tax demand due to clerical errors. Management expects the demand to be recomputed to nil following rectification.

Value

₹2.01 Cr

Par Drugs & Chemicals Q4 FY26 Results: Net Profit ₹0.9 Cr, Down 47.1% YoY

Par Drugs & Chemicals Ltd reported revenue from operations of ₹19.6 Cr (-12.1% YoY) and net profit of ₹0.9 Cr (-47.1% YoY) for Q4 FY26.

Key figure

Net profit ₹0.9 Cr · -47.1% YoY

Par Drugs & Chemicals Financial Results

Par Drugs and Chemicals Limited approved its FY2026 audited financial results and authorized a ₹90 Crore investment limit. The board also renewed its ₹1.61 Crore banking facility.

Par Drugs & Chemicals Board Meeting Outcome

Par Drugs approved its FY2026 audited results and renewed a ₹1.61 Crore banking facility. The board also noted a ₹25.14 Lakh employee bonus payment.

Value

₹1.88 Cr